NCT04827537View on ClinicalTrials.gov

Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Giardia Lamblia Infection
Interventions
DRUG

20-hydroxyecdysone Oral

100 mg (one pill) x two times a day orally, 10 consecutive days

DRUG

Metronidazole Oral

500 mg (one pill) x two times a day orally, 10 consecutive days

DRUG

Placebo Oral

100 mg (one pill) x two times a day orally, 10 consecutive days

Trial Locations (1)

100133

Research institute of epidemiology, microbiology and infectious diseases, Tashkent

All Listed Sponsors
lead

Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan

OTHER_GOV